|
|
TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium
|
|
|
TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results
|
|
|
TherapeuticsMD Announces Participation in Upcoming Investor Conferences
|
|
|
TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021
|
|
|
TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
|
|
|
TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock
|
|
|
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
|
